$NVAX
NOVAVAX INC Stock $nvax

$nvax Overview Financials Valuation SEC Filings Company Website

2015 Q3 Form 10-Q Financial Statement

#000114420415047742 Filed on August 10, 2015

Income Statement

Concept	2015 Q3	2015 Q2	2014 Q2
Revenue	$6.525M	$14.00M	$8.259M
YoY Change	-20.56%	69.46%	133.9%
Cost Of Revenue	$2.700M	$2.700M	$5.102M
YoY Change	-32.95%	-47.08%	212.62%
Gross Profit	$3.825M	$11.30M	$3.157M
YoY Change	-8.65%	257.81%	66.25%
Gross Profit Margin	58.62%	80.71%	38.22%
Selling, General & Admin	$9.100M	$7.100M	$5.800M
YoY Change	89.58%	22.41%	45.0%
% of Gross Profit	237.91%	62.85%	183.72%
Research & Development	$30.66M	$27.73M	$15.20M
YoY Change	59.55%	82.4%	40.96%
% of Gross Profit	801.67%	245.48%	481.53%
Depreciation & Amortization	$1.500M	$1.500M	$1.000M
YoY Change	50.0%	50.0%	66.67%
% of Gross Profit	39.22%	13.28%	31.68%
Operating Expenses	$30.66M	$27.73M	$15.20M
YoY Change	59.55%	82.4%	40.96%
Operating Profit	-$33.20M	-$20.82M	-$17.85M
YoY Change	67.76%	16.64%	38.4%
Interest Expense	$64.00K	$26.00K	$51.00K
YoY Change	36.17%	-49.02%	13.33%
% of Operating Profit
Other Income/Expense, Net	-$51.00K	$72.00K	$18.00K
YoY Change	168.42%	300.0%
Pretax Income	-$33.10M	-$20.60M	-$17.86M
YoY Change	67.79%	15.32%	41.46%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$33.12M	-$20.64M	-$17.86M
YoY Change	67.89%	15.55%	41.41%
Net Earnings / Revenue	-507.59%	-147.48%	-216.3%
Basic Earnings Per Share
Diluted Earnings Per Share	-$2.452M	-$1.537M	-$1.642M
COMMON SHARES
Basic Shares Outstanding	269.6M shares	268.0M shares	209.3M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2015 Q3	2015 Q2	2014 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$290.2M	$314.9M	$152.5M
YoY Change	62.94%	106.49%	275.62%
Cash & Equivalents	$138.1M	$167.4M	$103.9M
Short-Term Investments	$152.0M	$147.6M	$149.7M
Other Short-Term Assets	$15.60M	$13.20M	$269.0K
YoY Change	3780.6%	4807.06%	1245.0%
Inventory
Prepaid Expenses			$5.116M
Receivables	$4.300M	$2.342M	$3.719M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$310.1M	$333.0M	$166.6M
YoY Change	61.53%	99.86%	267.25%
LONG-TERM ASSETS
Property, Plant & Equipment	$29.42M	$26.13M	$15.12M
YoY Change	68.2%	72.8%	13.54%
Goodwill	$53.06M	$53.31M	$57.91M
YoY Change	-5.54%	-7.94%	74.73%
Intangibles	$11.01M	$11.36M	$15.09M
YoY Change	-20.04%	-24.72%
Long-Term Investments			$56.40M
YoY Change
Other Assets	$1.044M	$918.0K	$159.0K
YoY Change	556.6%	477.36%	-52.54%
Total Long-Term Assets	$94.53M	$91.72M	$145.4M
YoY Change	-5.97%	-36.91%	205.74%
TOTAL ASSETS
Total Short-Term Assets	$310.1M	$333.0M	$166.6M
Total Long-Term Assets	$94.53M	$91.72M	$145.4M
Total Assets	$404.6M	$424.7M	$312.0M
YoY Change	38.33%	36.13%	235.77%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$8.201M	$7.117M	$4.495M
YoY Change	175.66%	58.33%	52.58%
Accrued Expenses	$13.27M	$16.52M	$11.00M
YoY Change	-3.22%	50.23%	52.26%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$500.0K	$500.0K	$900.0K
YoY Change	-44.44%	-44.44%	50.0%
Total Short-Term Liabilities	$24.87M	$27.05M	$17.48M
YoY Change	33.47%	54.77%	55.29%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$100.0K	$900.0K
YoY Change	-100.0%	-88.89%	-52.63%
Other Long-Term Liabilities	$3.094M	$73.00K	$1.507M
YoY Change	121.16%	-95.16%	-85.78%
Total Long-Term Liabilities	$3.094M	$73.00K	$1.507M
YoY Change	121.16%	-95.16%	-87.94%
TOTAL LIABILITIES
Total Short-Term Liabilities	$24.87M	$27.05M	$17.48M
Total Long-Term Liabilities	$3.094M	$73.00K	$1.507M
Total Liabilities	$37.62M	$37.10M	$30.26M
YoY Change	21.88%	22.59%	27.72%
SHAREHOLDERS EQUITY
Retained Earnings	-$571.2M	-$538.1M	-$441.8M
YoY Change	23.76%	21.79%	16.03%
Common Stock	$2.703M	$2.691M	$2.386M
YoY Change	13.14%	12.78%	55.74%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$2.450M	$2.450M	$2.450M
YoY Change	0.0%	0.0%	0.0%
Treasury Stock Shares	455.4K shares		455.4K shares
Shareholders Equity	$367.0M	$387.6M	$281.7M
YoY Change
Total Liabilities & Shareholders Equity	$404.6M	$424.7M	$312.0M
YoY Change	38.33%	36.13%	235.77%

Cashflow Statement

Concept	2015 Q3	2015 Q2	2014 Q2
OPERATING ACTIVITIES
Net Income	-$33.12M	-$20.64M	-$17.86M
YoY Change	67.89%	15.55%	41.41%
Depreciation, Depletion And Amortization	$1.500M	$1.500M	$1.000M
YoY Change	50.0%	50.0%	66.67%
Cash From Operating Activities	-$28.50M	-$12.30M	-$11.00M
YoY Change	80.38%	11.82%	44.74%
INVESTING ACTIVITIES
Capital Expenditures	-$4.400M	-$4.300M	-$900.0K
YoY Change	41.94%	377.78%	-47.06%
Acquisitions
YoY Change
Other Investing Activities	-$4.800M	-$35.10M	-$101.8M
YoY Change	-90.61%	-65.52%	6262.5%
Cash From Investing Activities	-$9.200M	-$39.40M	-$102.8M
YoY Change	-82.99%	-61.67%	3112.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	8.500M	4.100M	107.7M
YoY Change	1600.0%	-96.19%	2347.73%
NET CHANGE
Cash From Operating Activities	-28.50M	-12.30M	-11.00M
Cash From Investing Activities	-9.200M	-39.40M	-102.8M
Cash From Financing Activities	8.500M	4.100M	107.7M
Net Change In Cash	-29.20M	-47.60M	-6.100M
YoY Change	-57.93%	680.33%	-4.69%
FREE CASH FLOW
Cash From Operating Activities	-$28.50M	-$12.30M	-$11.00M
Capital Expenditures	-$4.400M	-$4.300M	-$900.0K
Free Cash Flow	-$24.10M	-$8.000M	-$10.10M
YoY Change	89.76%	-20.79%	71.19%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies	0	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	32335000	USD
CY2015Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	147554000	USD
CY2014Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	135721000	USD
CY2015Q2	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	0	USD
CY2015Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2342000	USD
CY2014Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	7510000	USD
CY2015Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	167384000	USD
CY2014Q4	us-gaap	Liabilities Liabilities	46384000	USD
CY2014Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	297000	USD
CY2015Q2	us-gaap	Government Contract Receivable Unbilled Amounts GovernmentContractReceivableUnbilledAmounts	2498000	USD
CY2014Q4	us-gaap	Government Contract Receivable Unbilled Amounts GovernmentContractReceivableUnbilledAmounts	3100000	USD
CY2015Q2	us-gaap	Assets Current AssetsCurrent	332979000	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	188158000	USD
CY2015Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	26134000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	19737000	USD
CY2015Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	11360000	USD
CY2014Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	12577000	USD
CY2015Q2	us-gaap	Goodwill Goodwill	53307000	USD
CY2014Q4	us-gaap	Goodwill Goodwill	54612000	USD
CY2015Q2	us-gaap	Assets Assets	424698000	USD
CY2014Q4	us-gaap	Assets Assets	276002000	USD
CY2015Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	7117000	USD
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	12908000	USD
CY2015Q2	us-gaap	Notes Payable Current NotesPayableCurrent	532000	USD
CY2014Q4	us-gaap	Notes Payable Current NotesPayableCurrent	603000	USD
CY2015Q2	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	1187000	USD
CY2014Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	1138000	USD
CY2015Q2	us-gaap	Liabilities Current LiabilitiesCurrent	27053000	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	34116000	USD
CY2015Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	2500000	USD
CY2014Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	2500000	USD
CY2015Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	149000	USD
CY2014Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	395000	USD
CY2015Q2	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	7320000	USD
CY2014Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	7734000	USD
CY2015Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	73000	USD
CY2015Q2	us-gaap	Liabilities Liabilities	37095000	USD
CY2015Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies	0	USD
CY2015Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q2	us-gaap	Common Stock Value CommonStockValue	2691000	USD
CY2015Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	934176000	USD
CY2014Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1639000	USD
CY2014Q4	us-gaap	Treasury Stock Value TreasuryStockValue	2450000	USD
CY2014Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-6605000	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	229618000	USD
CY2014Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	70000	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	276002000	USD
CY2014Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	729373000	USD
CY2014Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	9195000	USD
CY2014Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	19397000	USD
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	2393000	USD
CY2014Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	918000	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-493093000	USD
CY2014Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	25042000	USD
CY2015Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	1042000	USD
CY2015Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1046000	USD
CY2015Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-19595000	USD
CY2014Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	18000	USD
CY2015Q2	nvax	Research And Development Collaboration ResearchAndDevelopmentCollaboration	276000	USD
CY2014Q2	nvax	Research And Development Collaboration ResearchAndDevelopmentCollaboration	1018000	USD
CY2015Q2	us-gaap	Revenues Revenues	13996000	USD
CY2015Q2	us-gaap	Interest Expense InterestExpense	26000	USD
CY2014Q2	us-gaap	Interest Expense InterestExpense	51000	USD
CY2015Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-538104000	USD
CY2015Q2	us-gaap	Treasury Stock Value TreasuryStockValue	2450000	USD
CY2015Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-8710000	USD
CY2015Q2	us-gaap	Stockholders Equity StockholdersEquity	387603000	USD
CY2015Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	424698000	USD
CY2015Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	13201000	USD
CY2015Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1695000	USD
CY2015Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	16522000	USD
CY2015Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	918000	USD
CY2015Q2	us-gaap	Contracts Revenue ContractsRevenue	13720000	USD
CY2014Q2	us-gaap	Contracts Revenue ContractsRevenue	7241000	USD
CY2014Q2	us-gaap	Revenues Revenues	8259000	USD
CY2015Q2	us-gaap	Contract Revenue Cost ContractRevenueCost	2687000	USD
CY2014Q2	us-gaap	Contract Revenue Cost ContractRevenueCost	5102000	USD
CY2014Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15202000	USD
CY2015Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7088000	USD
CY2014Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5806000	USD
CY2015Q2	us-gaap	Costs And Expenses CostsAndExpenses	34817000	USD
CY2014Q2	us-gaap	Costs And Expenses CostsAndExpenses	26110000	USD
CY2015Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-20821000	USD
CY2014Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-17851000	USD
CY2015Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	268083000	shares
CY2014Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	217178000	shares
CY2015Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.08
CY2014Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.08
CY2015Q2	us-gaap	Net Income Loss NetIncomeLoss	-20641000	USD
CY2014Q2	us-gaap	Net Income Loss NetIncomeLoss	-17864000	USD
CY2015Q2	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	0	USD
CY2014Q2	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	0	USD
CY2014Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	27000	USD
CY2015Q2	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	0	USD
CY2014Q2	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	0	USD
CY2014Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-1410000	USD
CY2014Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-1383000	USD
CY2014Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-19247000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-45011000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-31674000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2795000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-593000	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	-365000	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	-45000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	2892000	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-1214000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-5364000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1828000	USD
	us-gaap	Increase Decrease In Unbilled Receivables IncreaseDecreaseInUnbilledReceivables	-602000	USD
	us-gaap	Increase Decrease In Unbilled Receivables IncreaseDecreaseInUnbilledReceivables	-149000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3449000	USD
CY2015Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	4000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1823000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-8339000	USD
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	33000	USD
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	32000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-243000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-42812000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1279000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	109000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-31372000	USD
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	9240000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-21619000	USD
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	1846000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-93080000	USD
	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	-315000	USD
	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	-338000	USD
	us-gaap	Proceeds From Repayments Of Restricted Cash Financing Activities ProceedsFromRepaymentsOfRestrictedCashFinancingActivities	0	USD
CY2014Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	135786000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	119471000	USD
	us-gaap	Interest Paid InterestPaid	57000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	63350000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	13440000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-4000	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	104686000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	840000	USD
CY2014Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	12577000	USD
	us-gaap	Proceeds From Repayments Of Restricted Cash Financing Activities ProceedsFromRepaymentsOfRestrictedCashFinancingActivities	-1000	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-80000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	135049000	USD
CY2015Q2	us-gaap	Available For Sale Securities AvailableForSaleSecurities	147554000	USD
CY2014Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	135721000	USD
	us-gaap	Available For Sale Securities Gross Unrealized Gains AvailableForSaleSecuritiesGrossUnrealizedGains	18000	USD
CY2014	us-gaap	Available For Sale Securities Gross Unrealized Gains AvailableForSaleSecuritiesGrossUnrealizedGains	8000	USD
	us-gaap	Available For Sale Securities Gross Unrealized Loss AvailableForSaleSecuritiesGrossUnrealizedLoss	34000	USD
CY2014	us-gaap	Available For Sale Securities Gross Unrealized Loss AvailableForSaleSecuritiesGrossUnrealizedLoss	73000	USD
	us-gaap	Goodwill Translation Adjustments GoodwillTranslationAdjustments	-1305000	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	13018000	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1658000	USD
CY2014Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1307000	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	11360000	USD
CY2014Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	13884000	USD
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	15000	shares
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	15000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	0	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	4.48
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	4.48
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	0
CY2015Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2580000	USD
CY2014Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1852000	USD
	dei	Document Type DocumentType	10-Q
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Period End Date DocumentPeriodEndDate	2015-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Registrant Name EntityRegistrantName	NOVAVAX INC
	dei	Entity Central Index Key EntityCentralIndexKey	0001000694
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Trading Symbol TradingSymbol	NVAX
CY2015Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	269640511	shares
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	47000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-1000	USD
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	0	USD
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	615000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-2152000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-1543000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-2105000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-2159000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-47116000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-33833000	USD
	us-gaap	Contracts Revenue ContractsRevenue	22966000	USD
	us-gaap	Contracts Revenue ContractsRevenue	12713000	USD
	nvax	Research And Development Collaboration ResearchAndDevelopmentCollaboration	906000	USD
	nvax	Research And Development Collaboration ResearchAndDevelopmentCollaboration	3008000	USD
	us-gaap	Revenues Revenues	23872000	USD
	us-gaap	Revenues Revenues	15721000	USD
	us-gaap	Contract Revenue Cost ContractRevenueCost	5307000	USD
	us-gaap	Contract Revenue Cost ContractRevenueCost	8123000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	50769000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	29720000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12931000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10114000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	69007000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	47957000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-45135000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-32236000	USD
	us-gaap	Investment Income Net InvestmentIncomeNet	256000	USD
	us-gaap	Investment Income Net InvestmentIncomeNet	32000	USD
CY2014Q2	us-gaap	Investment Income Net InvestmentIncomeNet	20000	USD
CY2015Q2	us-gaap	Investment Income Net InvestmentIncomeNet	134000	USD
	us-gaap	Interest Expense InterestExpense	62000	USD
	us-gaap	Interest Expense InterestExpense	103000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-70000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	18000	USD
	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	0	USD
	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	615000	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.18
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.15
CY2015Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2015Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2015Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2015Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	600000000	shares
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2015Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	269095405	shares
CY2015Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	268639975	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	239287294	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	238831864	shares
	us-gaap	Nature Of Operations NatureOfOperations	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="center"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt">Note 1 Organization</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Novavax, Inc. (“Novavax,” and together with its wholly owned subsidiary “Novavax AB,” the “Company”) is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company’s product pipeline targets a variety of infectious diseases with vaccine candidates currently in clinical development for respiratory syncytial virus (“RSV”), seasonal influenza, pandemic influenza and Ebola virus (“EBOV”). The Company has additional preclinical stage programs in a variety of infectious diseases, including Middle East Respiratory Syndrome (“MERS”).</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.25in" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.25in" align="justify"><strong><i><font style="FONT-SIZE: 10pt">Use of Estimates</font></i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
	nvax	Services Purchased ServicesPurchased	6700000	USD
	nvax	Services Purchased ServicesPurchased	1000000	USD
	nvax	Remaining Obligation Under Master Services Agreement RemainingObligationUnderMasterServicesAgreement	800000	USD
CY2015Q2	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	8700000	USD
CY2015Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	800000	USD
CY2014Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	800000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	23248254	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	16514230	shares
	us-gaap	Contracts Revenue ContractsRevenue	101000000	USD
CY2015Q2	us-gaap	Equity Method Investment Ownership Percentage EquityMethodInvestmentOwnershipPercentage	0.2	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0213	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0222	pure
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4514000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2892000	USD
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.42
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.92
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.42
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.48
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0137	pure
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0133	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0124	pure
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0213	pure
	nvax	Available For Sale Securities Number Of Securities Owned AvailableForSaleSecuritiesNumberOfSecuritiesOwned	47000	shares
	nvax	Available For Sale Securities Number Of Securities Owned Unrealized Losses AvailableForSaleSecuritiesNumberOfSecuritiesOwnedUnrealizedLosses	33000	shares
CY2015Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	865000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	400000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	600000	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	865000	USD
	nvax	Sale Of Common Stock Under Sales Agreement SaleOfCommonStockUnderSalesAgreement	679000	USD
	nvax	Sale Of Common Stock Under Sales Agreement SaleOfCommonStockUnderSalesAgreement	0	USD
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	254727000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	213075000	shares
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	12000	USD
	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	0	USD
	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	171000	USD
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.5418	pure
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.5287	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.5358	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.5247	pure
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.6839	pure
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.5381	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.6839	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.6793	pure
CY2015Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	433000	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	865000	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	865000	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	865000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	6000000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	1700000	USD
CY2015Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	35200000	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y7M6D

Files In Submission

Name	View Source	Status
0001144204-15-047742-index-headers.html	Edgar Link	pending
0001144204-15-047742-index.html	Edgar Link	pending
0001144204-15-047742.txt	Edgar Link	pending
0001144204-15-047742-xbrl.zip	Edgar Link	pending
ex10-1pg01.jpg	Edgar Link	pending
ex10-1pg02.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
nvax-20150630.xml	Edgar Link	completed
nvax-20150630.xsd	Edgar Link	pending
nvax-20150630_cal.xml	Edgar Link	unprocessable
nvax-20150630_def.xml	Edgar Link	unprocessable
nvax-20150630_lab.xml	Edgar Link	unprocessable
nvax-20150630_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tex10-5.jpg	Edgar Link	pending
tex10-6.jpg	Edgar Link	pending
tex10-7.jpg	Edgar Link	pending
v416489_10q.htm	Edgar Link	pending
v416489_ex10-1.htm	Edgar Link	pending
v416489_ex10-3.htm	Edgar Link	pending
v416489_ex10-4.htm	Edgar Link	pending
v416489_ex10-5.htm	Edgar Link	pending
v416489_ex3-1.htm	Edgar Link	pending
v416489_ex31-1.htm	Edgar Link	pending
v416489_ex31-2.htm	Edgar Link	pending
v416489_ex32-1.htm	Edgar Link	pending
v416489_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NVAX
NOVAVAX INC Stock $nvax

2015 Q3 Form 10-Q Financial Statement

#000114420415047742 Filed on August 10, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NVAX NOVAVAX INC Stock $nvax

2015 Q3 Form 10-Q Financial Statement

#000114420415047742 Filed on August 10, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NVAX
NOVAVAX INC Stock $nvax